Učitavanje...
Practical management of patients with myelofibrosis receiving ruxolitinib
Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, IN...
Spremljeno u:
| Izdano u: | Expert Rev Hematol |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2013
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8201600/ https://ncbi.nlm.nih.gov/pubmed/24083419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17474086.2013.827413 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|